Source :Health Policy Watch 15th April, 2019 Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use … Continue reading
Treatment Action Campaign; December 4, 2015. CApe Town – Activists at the 46th Union World Conference on Lung Health demanded that pharmaceutical company Sanofi be held accountable for endangering failing to provide life-saving products to people and children living with TB and … Continue reading
MSF; December 3, 2015. Cape Town – Nearly three years since the first of two new tuberculosis (TB) medicines became available, the drugs remain out of reach for people who need them, with just two percent of people eligible for these treatments … Continue reading
Huffington Post; November 12, 2015. Brazil, India, Russia and China have gone through a period of rapid economic development, making them important global players in the 21st century. However, they are also the countries that might be affected most severely by growing antimicrobial … Continue reading
The Guardian; Pharmaceutical companies should be given cash incentives of up to $3bn to find and develop new antibiotics desperately needed to keep infections at bay, according to a UK government review. Jim O’Neill, the economist and former chair of … Continue reading
onmedica; Ocober 26, 2015. By Adrian O’Dowd. A joint fund between the UK and China is to be launched to boost a global response to the growing problem of antimicrobial resistance (AMR) through dedicated research.
Source: IP watch, October 9, 2015 A new report from Chatham House presenting suggestions for novel business models for antibiotics calls for models in which the return on investment in research and development is not dependent on the volume of … Continue reading